Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics.
Thymopentin, a potent immunomodulating drug, was incorporated into pH-sensitive chitosan nanoparticles prepared by ionic gelation of chitosan with tripolyphosphate anions and then coated with Eudragit S100 to improve the stability and the oral bioavailability. Nanoparticles particle size and zeta potential were measured by photo correction spectroscopy and laser Dopper anemometry. Its morphology was examined by environment scan electron microscope. The encapsulation efficiency and the release in vitro were determined by HPLC. Enzymatic stabilization was expressed by the enzymatic degradation of aminopeptidase. Biological activity of TP5 loaded in nanoparticles was assayed by lymphocyte proliferation test in vitro and the immune function (CD4+/CD8+) of irradiated rat in vivo. The results obtained demonstrated that the average sizes of pH-sensitive chitosan nanoparticles were 175.6 +/- 17 nm, the zeta potential was 28.44 +/- 0.5 mV and the encapsulation efficiency was 76.70 +/- 2.6%. The cumulative release percentages of thymopentin from the pH-sensitive nanoparticles were 24.65%, 41.01%, and 81.44% incubated in different medium, 0.1 N HCl, pH 5.0 PBS, and pH 7.4 PBS, respectively. The pH-sensitive chitosan nanoparticles could efficiently protect TP5 from enzymatic degradation and prolong the degradation half-time of TP5 from 1.5 min to 15 min. It was demonstrated from the lymphocyte proliferation test that the nanoparticle-encapsulated TP5 still kept its biological activity. In immunosuppression rats, the lowered T-lymphocyte subsets values were significantly increased and the raised CD4+/CD8+ ratio was evidently reduced. These results indicated that pH-sensitive chitosan nanoparticles may be used as the vector in oral drug delivery system for TP5.
Zheng
Ai-Ping
AP
Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Wang
Jian-Cheng
JC
Lu
Wan-Liang
WL
Zhang
Xuan
X
Zhang
Hua
H
Wang
Xue-Qing
XQ
Zhang
Qiang
Q
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D000284:Administration, Oral; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002626:Chemistry, Pharmaceutical / Q000379:methods; D048271:Chitosan / Q000737:chemistry*; D003460:Crystallization / Q000379:methods; D004058:Diffusion; D004337:Drug Carriers / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D011109:Polymethacrylic Acids / Q000737:chemistry*; D016305:Thymopentin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*
D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D011109:Polymethacrylic Acids; C038300:methylmethacrylate-methacrylic acid copolymer; D048271:Chitosan; D016305:Thymopentin